VTv Receives Another U.S. Patent for Its Alzheimer’s Therapy Azeliragon

VTv Receives Another U.S. Patent for Its Alzheimer’s Therapy Azeliragon
VTv Therapeutics has received another U.S. patent for azeliragon, an Alzheimer’s treatment that targets a receptor involved in the disease's inflammation. Azekuragan is an antagonist of the advanced glycation endproducts, or RAGE, receptor, meaning that it prevents the receptor from acting. Found in low levels in a healthy brain, RAGE numbers increase during inflammation. The patent, number 9,717,710 (‘710), covers the use of 5 mg of azeliragon a day to treat people with mild cases of Alzheimer's. It runs through October 2034. VTv expects the U.S. Food and Drug Administration to add the patent to its 
Subscribe or to access all post and page content.